Evidence map›Paper›PMID 34145095›Full record

SynthesisThe Indian journal of medical research2020

Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis.

Kamolyut Lapumnuaypol, David Pisarcik, Prapaipan Putthapiban, Weera Sukhumthammarat, Karn Wijarnpreecha, Charat Thongprayoon, Patompong Ungprasert

Open access · diamondAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in The Indian journal of medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. From Cure to Complexity: Post-SVR Liver and Metabolic Trajectories in Diabetic Patients.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Kamolyut LapumnuaypolDepartment of Internal Medicine, Albert Einstein Medical Center, PA, USA.
David PisarcikDepartment of Internal Medicine, Philadelphia College of Osteopathic Medicine, PA, USA.
Prapaipan PutthapibanDepartment of Internal Medicine, Albert Einstein Medical Center, PA, USA.
Weera SukhumthammaratDepartment of Internal Medicine, Albert Einstein Medical Center, PA, USA.
Karn WijarnpreechaDepartment of Gastroenterology, Mayo Clinic Hospital, Gastroenterology - Jacksonville, FL, USA.
Charat ThongprayoonDepartment of Nephrology, Mayo Clinic, Nephrology & Hypertension Rochester, MN, USA.
Patompong UngprasertDepartment of Research & Development, Division of Clinical Epidemiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Einstein Medical Center Philadelphia · USMayo Clinic Hospital · USMayo Clinic in Arizona · USPhiladelphia College of Osteopathic Medicine · USSiriraj Hospital · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & objectives: Several epidemiologic studies have demonstrated that type 2 diabetes mellitus (T2DM) is more prevalent in patients infected with hepatitis C virus (HCV), and the eradication of HCV has been shown to decrease the risk of T2DM. This meta-analysis was undertaken to see if treatment with direct-acting antiviral (DAA) agents would improve glycaemic control among HCV-infected patients with T2DM. Methods: A systematic review was conducted using MEDLINE and EMBASE databases since inception to February 2018. Eligible studies must be cohort studies that recruited HCV-infected patients with T2DM and received DAA therapy. The studies must report the change of haemoglobin A1c (HbA1c) level (before vs. after DAA therapy). Patients who achieved sustained virologic response (SVR) were included in the meta-analysis. The mean HbA1c level and standard deviation of participants were extracted from each study to calculate the mean difference (MD). Pooled MD was then calculated using the random effects model. Results: Four cohort studies with 2648 patients were included. Among HCV-infected T2DM patients who achieved SVR with DAA agents, the mean HbA1c level after treatment was significantly lower than the mean HbA1c level before treatment, with the pooled MD of -0.50 per cent (95% confidence interval, -0.66 to -0.34, I Interpretation & conclusions: Treatment with DAA agents was found to be associated with a significant reduction of post-treatment HbA1c level compared with pre-treatment HbA1c level among T2DM patients who achieved SVR.

Indexed as

Diabetes Mellitus, Type 2Hepatitis CHepatitis C, ChronicAntiviral AgentsGlycated HemoglobinHepacivirusHumansSustained Virologic ResponseAntiviral AgentsGlycated HemoglobinDiabetes mellitusdirect-acting antiviral agentshaemoglobin A1chepatitis C virusmeta-analysis

Identifiers

PMID34145095
PMCPMC8224154
OpenAlexW3173099300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.